Improved platform for breast cancer circulating tumor cell enrichment and characterization with next-generation sequencing technology.

Catalin Mihalcioiu(McGill University Health Centre), Richard Kremer(McGill University Health Centre)

PubMed

January 1, 2023

Cited by 6

Related Papers

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

|New England Journal of Medicine|2014|5.3k

Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy

|JAMA Oncology|2018|345

Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma

|Journal of Clinical Oncology|2020|226

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

|The Lancet Oncology|2018|216

Spatially mapping the immune landscape of melanoma using imaging mass cytometry

|Science Immunology|2022|131